Nefazodone alters NPY immunostaining in rat arcuate-paraventricular projection without changes in food intake and body weight.
Nefazodone is an antidepressant drug that inhibits serotonin and noradrenaline reuptake. The aim of the present work was to study the effects of nefazodone on food intake, body weight, adiposity and hypothalamic NPY immunostaining in rats. For this purpose, male Sprague-Dawley rats (3-month-old) were administered with nefazodone (20 mg/kg; i.p) daily for two weeks. The control group was given 0.9% NaCl solution. Hypothalamic arcuate, paraventricular, periventricular, supraoptic and suprachiasmatic nuclei and the lateral hypothalamic area were immunostained for NPY. Chronic nefazodone administration in rats did not modify food intake, body weight and adipose depot size (subcutaneous, perirenal and epididymal white adipose tissues, and interscapular brown adipose tissue). However, a significant decrease in paraventricular NPY immunostaining was found in the nefazodone group compared with the control group. No changes in other hypothalamic regions such as arcuate, periventricular, supraoptic and suprachiasmatic nuclei, and lateral and medial preoptic areas were observed. Because nefazodone is an alpha1-adrenoceptor antagonist, it can be proposed that the expected decrease in food intake after nefazodone administration, due to its effects on NPY arcuate-paraventricular projection, could be masked by the opposite orexigenic effect of alpha1-adrenoceptor blockade.
Saracíbar
G
G
Department of Physiology, School of Pharmacy, University of the Basque Country, Vitoria, Spain.
Casado
A
A
Rodríguez
V M
VM
Portillo
M P
MP
Macarulla
M T
MT
Abecia
L C
LC
Echevarría
Enrique
E
Casis
L
L
D000273:Adipose Tissue / Q000187:drug effects / Q000502:physiology; D002001:Adipose Tissue, Brown / Q000187:drug effects / Q000502:physiology; D000818:Animals; D018687:Antidepressive Agents, Second-Generation / Q000494:pharmacology*; D001111:Arcuate Nucleus of Hypothalamus / Q000187:drug effects / Q000378:metabolism*; D001835:Body Weight / Q000187:drug effects / Q000502:physiology*; D002149:Energy Intake; D007150:Immunohistochemistry; D008297:Male; D009478:Neuropeptide Y / Q000378:metabolism*; D010286:Paraventricular Hypothalamic Nucleus / Q000187:drug effects / Q000378:metabolism*; D010879:Piperazines; D051381:Rats; D017207:Rats, Sprague-Dawley; D014230:Triazoles / Q000494:pharmacology*
D018687:Antidepressive Agents, Second-Generation; D009478:Neuropeptide Y; D010879:Piperazines; D014230:Triazoles; C051752:nefazodone